Novo Nordisk's stocks face YTD struggles due to trial results and tariffs, but strong fundamentals and outlook justify a Buy.

That's good news for Recursion Pharmaceuticals ( RXRX 3.67%), a biotech company that's already pioneering the use of AI in drug development. Recursion's shares soared on the news, but the stock ...

Shares of obesity drug developers were volatile this week amid good news for Eli Lilly's (LLY) drug candidate orforglipron, ...

Eli Lilly & Co.'s stock soared 14% Thursday, to put it on track for its biggest one-day gain in about 25 years, after the drugmaker reported positive results from a late-stage trial of a GLP-1 ...

Fintel reports that on April 17, 2025, BMO Capital downgraded their outlook for Novo Nordisk A (NYSE:NVO) from Outperform to ...

Growth is driven by the rising prevalence of diabetes among the elderly, necessitating efficient insulin delivery solutions ...

President Donald Trump has ordered the Department of Health and Human Services to standardize Medicare payments in an effort ...

We recently published a list of 10 Best Pharma Stocks to Buy for Long Term Growth. In this article, we are going to take a ...

Sparrow Quantum, a Copenhagen-based startup specializing in single-photon emitters suitable for a range of quantum technology ...

So far this year, Pfizer shares have dropped 17.4%, while Novo Nordisk's stock has tumbled 24% and Lilly shares have slipped 3.2%. The SPDR S&P Pharmaceuticals ETF XPH has shed 12.1% year to date and ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.